Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
NEW YORK, March 16, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of HeartWare International, Inc. (“HeartWare”) (NASDAQ:HTWR) between June 10, 2014 and January 11, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired HeartWare securities between June 10, 2014 and January 11, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/heartware.
The complaint alleges that during the Class Period, HeartWare and certain of its senior executives made false and misleading statements and omitted material information. In particular, it is alleged that after the U.S. Food and Drug Administration issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that these concerns therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you suffered a loss in HeartWare you have until March 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/heartware.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
